Adherence to and persistence with lacosamide, perampanel, lamotrigine, and levetiracetam in adult patients with focal epilepsy in Japan: A descriptive cohort study using a claims database.

[1]  J. Zelano,et al.  Big data analysis of ASM retention rates and expert ASM algorithm: A comparative study , 2022, Epilepsia.

[2]  K. Usami,et al.  Complications associated with the use of enzyme-inducing and non-enzyme-inducing anti-seizure medications in the Japanese population: A retrospective cohort study , 2022, Epilepsy & Behavior.

[3]  J. Wheless,et al.  Perampanel in real-world clinical care of adolescent and adult patients with epilepsy: Results from the retrospective Phase IV PROVE Study , 2022, Seizure.

[4]  Jung-Ae Kim,et al.  Evaluation of persistence and healthcare utilization in patients treated with anti-seizure medications as add-on therapy: A nationwide cohort study in South Korea , 2021, Epilepsy & Behavior.

[5]  Y. Chinvarun.  A retrospective, real‐world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience , 2021, Epilepsia open.

[6]  Kunihiko Takahashi,et al.  Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: Matched case-control and cohort studies. , 2021, Allergology international : official journal of the Japanese Society of Allergology.

[7]  S. Kimura,et al.  Data resource profile: JMDC claims database sourced from health insurance societies , 2021, Journal of general and family medicine.

[8]  A. Ikeda,et al.  Prescription patterns of antiepileptic drugs for adult patients with newly diagnosed focal epilepsy from 2006 to 2017 in Japan , 2020, Epilepsy Research.

[9]  M. Eadie,et al.  The outcome of altering antiepileptic drug therapy before pregnancy , 2020, Epilepsy & Behavior.

[10]  Sung-chul Lim,et al.  Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study) , 2020, Epilepsia open.

[11]  Katsuhiro Kobayashi,et al.  Action of antiepileptic drugs on neurons , 2019, Brain and Development.

[12]  E. Beghi.  The Epidemiology of Epilepsy , 2019, Neuroepidemiology.

[13]  D. Lozsádi,et al.  Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting , 2019, Seizure.

[14]  K. Higgins,et al.  Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. , 2019, Journal of comparative effectiveness research.

[15]  J. Sander,et al.  Epilepsy in adults , 2019, The Lancet.

[16]  Yoshiro Saito,et al.  The Medication Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label , 2018, Clinical pharmacology and therapeutics.

[17]  Trisha Acri,et al.  Studies of Medication Adherence , 2013, Pharmacoepidemiology.

[18]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[19]  J. Walsh,et al.  Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. , 2018, Journal of comparative effectiveness research.

[20]  M. De Backer,et al.  Lacosamide monotherapy in clinical practice: A retrospective chart review , 2018, Acta neurologica Scandinavica.

[21]  Patrick Kwan,et al.  Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study , 2017, JAMA neurology.

[22]  D. W. Kim,et al.  One-Year Retention Study of Adjunctive Perampanel Treatment in Epilepsy Patients , 2017, Clinical neuropharmacology.

[23]  Josemir W Sander,et al.  Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center , 2017, Epilepsy & Behavior.

[24]  Josemir W Sander,et al.  Antiepileptic drug discontinuation by people with epilepsy in the general population , 2017, Epilepsia.

[25]  J. Peltola,et al.  Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market , 2017, Journal of Neurology.

[26]  Julie Jordan O Brien,et al.  Identifying the barriers to antiepileptic drug adherence among adults with epilepsy , 2017, Seizure.

[27]  M. Baulac,et al.  Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial , 2017, The Lancet Neurology.

[28]  H. Hamer,et al.  Nonadherence to antiepileptic drugs in Germany , 2016, Neurology.

[29]  Swu-Jane Lin,et al.  Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study , 2016, Medicine.

[30]  Philippe Ryvlin,et al.  Epilepsy: new advances , 2015, The Lancet.

[31]  M. Rogawski,et al.  Current understanding of the mechanism of action of the antiepileptic drug lacosamide , 2015, Epilepsy Research.

[32]  T. O'Brien,et al.  Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study , 2014, Epilepsia.

[33]  R. Willke,et al.  Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  G. Zaccara,et al.  Novel treatment options for epilepsy: focus on perampanel. , 2013, Pharmacological research.

[35]  J. López-Trigo,et al.  Rational polytherapy with lacosamide in clinical practice: Results of a Spanish cohort analysis RELACOVA , 2012, Epilepsy & Behavior.

[36]  J. Zeber,et al.  Variation in Antiepileptic Drug Adherence Among Older Patients with New-Onset Epilepsy , 2010, The Annals of pharmacotherapy.

[37]  S. Johannessen,et al.  Antiepileptic Drug Interactions - Principles and Clinical Implications , 2010, Current neuropharmacology.

[38]  M. Brookhart,et al.  Measuring concurrent adherence to multiple related medications. , 2009, The American journal of managed care.

[39]  Steve S. Chung,et al.  Comparative retention rates and long-term tolerability of new antiepileptic drugs , 2007, Seizure.

[40]  David F. Smith,et al.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[41]  K. Chan,et al.  Methods for evaluation of medication adherence and persistence using automated databases , 2006, Pharmacoepidemiology and drug safety.

[42]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[43]  R. Stern,et al.  Lamotrigine‐Associated Rash: Risk/Benefit Considerations in Adults and Children , 1999, Epilepsia.